3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Stomach Neoplasms
1
Peritoneal Neoplasms
1
Interventions
Fluorouracil
309
Oxaliplatin
260
Leucovorin
234
Capecitabine
198
Irinotecan
147
Gemcitabine
128
Cisplatin
126
Bevacizumab
119
Radiotherapy
72
Paclitaxel
64
Folfox protocol
56
Cetuximab
56
Drug Therapy
46
Sorafenib
45
Docetaxel
42
S 1 (combination)
40
Chemotherapy, Adjuvant
38
Neoadjuvant Therapy
37
pembrolizumab
36
130-nm albumin-bound paclitaxel
28
Surgical Procedures, Operative
27
regorafenib
25
lenvatinib
24
XELOX
24
Panitumumab
24
Radiation
23
Nivolumab
23
atezolizumab
22
Carboplatin
22
trifluridine tipiracil drug combination
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Hypericum extract LI 160
×
Gastrointestinal
×
Clear all
NCT02840331
2017-10-27
Hypericin-PDT
University Hospital Tuebingen
Phase 3
Unknown
50 enrolled